Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase NA 1Phase 4 1Phase 2 1Phase 1 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 52Neoplasms 44Prostatic Neoplasms 43Breast Neoplasms 38Neoplasm Metastasis 21Unspecified Adult Solid Tumor, Protocol Specific 19Lung Neoplasms 18Head and Neck Neoplasms 17Squamous Cell Carcinoma of Head and Neck 16Ovarian Neoplasms 15Advanced Solid Tumors 11Stomach Neoplasms 9Sarcoma 9Pancreatic Neoplasms 9Solid Tumor 8Melanoma 8Esophageal Neoplasms 8Carcinoma, Ovarian Epithelial 8Urinary Bladder Neoplasms 7Fallopian Tube Neoplasms 7Colorectal Neoplasms 7Small Cell Lung Carcinoma 6Salivary Gland Neoplasms 6Esthesioneuroblastoma, Olfactory 5Esophageal Squamous Cell Carcinoma 5Carcinoma, Renal Cell 5Breast Neoplasms, Male 5Triple Negative Breast Neoplasms 4Recurrence 4Endometrial Neoplasms 4

Interventions

aflutinib 3osimertinib 2Radiotherapy 2tipifarnib 1apatinib 1Radiosurgery 1Immune Checkpoint Inhibitors 1Gefitinib 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × NSCLC × Docetaxel × Clear all
NCT04413227 2020-06-02

A Phase Ib Study With Pegylated Recombinant Human Endostatin in Advanced / Metastatic NSCLC or Other Solid Tumors

Jiangsu Simcere Pharmaceutical Co., Ltd.

Phase 1 Unknown
30 enrolled
Other solid neoplasmThoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡